PMID- 35198340
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220225
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 14
IP  - 2
DP  - 2022 Feb
TI  - Clinical Outcomes of Acellular Dermal Matrix (SimpliDerm and AlloDerm 
      Ready-to-Use) in Immediate Breast Reconstruction.
PG  - e22371
LID - 10.7759/cureus.22371 [doi]
LID - e22371
AB  - Background The use of acellular dermal matrix (ADM) for post-mastectomy 
      reconstruction is considered by many surgeons to be an accepted component of 
      surgical technique. Early clinical experience is described for SimpliDerm(R) - a 
      novel human ADM (Aziyo Biologics, Silver Spring, USA), and AlloDerm(R) Ready-To-Use 
      (RTU) - an established ADM (Allergan Medical, Irvine, USA). Methods Records were 
      retrospectively reviewed from four sites between 2016 and 2021 of patients who 
      underwent immediate, two-stage reconstruction with either SimpliDerm (n=38) or 
      AlloDerm RTU (n=69) after mastectomy and were followed out to exchange to 
      permanent implant(s), tissue expander(s) explant, or death. Results Immediate 
      breast reconstruction with tissue expanders and ADM was performed on 107 patients 
      (181 breasts). Overall mean patient age was 51.4 +/- 12.4 years, and mean BMI was 
      28.0 +/- 5.8 kg/m(2). Significantly more patients in the SimpliDerm group were of 
      Hispanic or Latino ethnicity (34.2% vs. 7.2%; P<.001). Reconstructions were 
      predominantly prepectoral (82.3%). A total of 35 adverse events (AEs) occurred in 
      27 (25.2%) patients, with no difference in AE type, classification, or rates 
      between ADM groups. No AEs were considered related to either ADM. The observed AE 
      profiles and rates are similar to those published for other ADMs in immediate 
      breast reconstruction. Conclusions There continues to be a need for additional 
      clinically equivalent ADMs to provide physicians with more availability and 
      options for their practice. This retrospective, multisite study describes 
      comparable clinical outcomes with SimpliDerm and AlloDerm RTU through a median of 
      133.5 days (~four months) following immediate two-stage breast reconstruction.
CI  - Copyright (c) 2022, Tierney et al.
FAU - Tierney, Brian P
AU  - Tierney BP
AD  - Plastic Surgery, Tierney Plastic and Reconstructive Surgery, Nashville, USA.
FAU - De La Garza, Mauricio
AU  - De La Garza M
AD  - Plastic and Reconstructive Surgery, DHR Health, McAllen, USA.
FAU - Jennings, George R
AU  - Jennings GR
AD  - Plastic Surgery, Shoals Plastic Surgery Face and Body, Muscle Shoals, USA.
FAU - Weinfeld, Adam B
AU  - Weinfeld AB
AD  - Surgery and Perioperative Care, Dell Medical School at the University of Texas, 
      Austin, USA.
AD  - Plastic and Hand Surgery, Ascension Medical Group Seton, Austin, USA.
LA  - eng
PT  - Journal Article
DEP - 20220218
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC8856737
OTO - NOTNLM
OT  - acellular dermal matrix
OT  - adm
OT  - alloderm
OT  - breast cancer
OT  - breast reconstruction
OT  - complications
OT  - extracellular matrix
OT  - integuply
OT  - plastic and reconstructive surgery
OT  - simpliderm
COIS- The authors have declared financial relationships, which are detailed in the next 
      section.
EDAT- 2022/02/25 06:00
MHDA- 2022/02/25 06:01
PMCR- 2022/02/18
CRDT- 2022/02/24 05:43
PHST- 2022/02/17 00:00 [accepted]
PHST- 2022/02/24 05:43 [entrez]
PHST- 2022/02/25 06:00 [pubmed]
PHST- 2022/02/25 06:01 [medline]
PHST- 2022/02/18 00:00 [pmc-release]
AID - 10.7759/cureus.22371 [doi]
PST - epublish
SO  - Cureus. 2022 Feb 18;14(2):e22371. doi: 10.7759/cureus.22371. eCollection 2022 
      Feb.